June 15 (Reuters) – Adaptive Biotechnologies said on Monday it planned to separate its immune medicine business from its residual cancer-testing unit, as it reviews options for the drug-discovery business and focuses on testing.
• The company said it was reviewing options for the immune medicine business and expected to choose a preferred path by the end of 2026.
• Adaptive’s immune medicine platform helps conduct drug research by identifying therapeutic targets, and accelerate the development of precision medicines.
• Adaptive said the residual cancer-testing unit, which includes its clonoSEQ test, had reached profitability and expanded insurance coverage.
• ClonoSEQ is used to detect small traces of cancer that may remain after treatment and is also used in drug-development studies.
• The unit’s revenue rose to $212 million in 2025 from $103 million in 2023, the company said.
• Adaptive said the immune medicine business might be better placed outside the company’s diagnostics-focused model.
• The company said there was no assurance the review would result in a deal or any other outcome.
(Reporting by Kunal Das in Bengaluru; Editing by Anil D’Silva)
